Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
CRBP

CRBP - Corbus Pharmaceuticals Holdings Inc Stock Price, Fair Value and News

50.00USD-2.89 (-5.46%)Delayed

Market Summary

CRBP
USD50.00-2.89
Delayed
-5.46%

CRBP Stock Price

View Fullscreen

CRBP RSI Chart

CRBP Valuation

Market Cap

534.3M

Price/Earnings (Trailing)

-15.83

Price/Sales (Trailing)

481.06

Price/Free Cashflow

-18.46

CRBP Price/Sales (Trailing)

CRBP Profitability

Return on Equity

-34.81%

Return on Assets

-26.85%

Free Cashflow Yield

-5.42%

CRBP Fundamentals

CRBP Revenue

Revenue (TTM)

881.7K

CRBP Earnings

Earnings (TTM)

-33.8M

Earnings Growth (Yr)

61.12%

Earnings Growth (Qtr)

14%

Breaking Down CRBP Revenue

Last 7 days

13.3%

Last 30 days

13.3%

Last 90 days

14.5%

Trailing 12 Months

545.2%

How does CRBP drawdown profile look like?

CRBP Financial Health

Current Ratio

4.69

CRBP Investor Care

Shares Dilution (1Y)

153.53%

Diluted EPS (TTM)

-4.87

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20212.8M2.7M1.5M1.2M
202036.0M7.2M5.9M3.9M
20195.8M34.0M35.5M36.1M
20182.1M2.6M2.9M4.8M
20172.8M2.8M2.8M2.4M
2016964.1K1.3M1.6M1.9M
2015000648.4K

Tracking the Latest Insider Buys and Sells of Corbus Pharmaceuticals Holdings Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 14, 2024
holmer alan f
acquired
50,010
30.00
1,667
-
May 30, 2024
ben yong
acquired
-
-
2,783
-
May 30, 2024
catlin avery w
acquired
-
-
2,783
-
May 30, 2024
holmer alan f
acquired
-
-
2,783
-
May 30, 2024
jenkins john kenneth
acquired
-
-
2,783
-
May 30, 2024
jacques rachelle suzanne
acquired
-
-
2,783
-
May 30, 2024
salzmann peter
acquired
-
-
2,783
-
May 30, 2024
altmeyer anne
acquired
-
-
2,783
-
Apr 10, 2024
moran sean f.
acquired
53,610
30.00
1,787
chief financial officer
Mar 08, 2024
cormorant asset management, lp
bought
13,314,200
44.3806
300,000
-

1–10 of 50

Which funds bought or sold CRBP recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 17, 2024
Ikarian Capital, LLC
added
185
20,762,600
21,945,800
2.41%
May 16, 2024
COMERICA BANK
unchanged
-
33.00
39.00
-%
May 16, 2024
JANE STREET GROUP, LLC
new
-
1,271,380
1,271,380
-%
May 15, 2024
Prosight Management, LP
new
-
3,948,210
3,948,210
1.10%
May 15, 2024
Driehaus Capital Management LLC
new
-
2,474,440
2,474,440
0.03%
May 15, 2024
STATE STREET CORP
added
173
1,332,220
1,411,820
-%
May 15, 2024
Point72 Asset Management, L.P.
new
-
27,530,700
27,530,700
0.07%
May 15, 2024
MORGAN STANLEY
added
8,260
6,735,910
6,748,340
-%
May 15, 2024
PRICE T ROWE ASSOCIATES INC /MD/
new
-
7,554,000
7,554,000
-%
May 15, 2024
JANUS HENDERSON GROUP PLC
new
-
13,362,900
13,362,900
0.01%

1–10 of 46

Are Funds Buying or Selling CRBP?

Are funds buying CRBP calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CRBP
No. of Funds

Unveiling Corbus Pharmaceuticals Holdings Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 18, 2024
cormorant asset management, lp
19.30%
2,025,000
SC 13G/A
Feb 28, 2024
millennium management llc
5.3%
544,276
SC 13G
Feb 14, 2024
k2 healthventures equity trust llc
7.8%
10,524,401
SC 13G
Feb 14, 2024
paradigm biocapital advisors lp
0.0%
0
SC 13G
Feb 14, 2024
k2 healthventures equity trust llc
7.5%
342,113
SC 13G/A
Feb 12, 2024
ra capital management, l.p.
4.1%
430,182
SC 13G
Feb 12, 2024
adage capital partners gp, l.l.c.
7.70%
796,392
SC 13G
Feb 09, 2024
integrated core strategies (us) llc
4.0%
412,321
SC 13G
Feb 05, 2024
paradigm biocapital advisors lp
9.0%
399,658
SC 13G
Feb 05, 2024
cormorant global healthcare master fund, lp
14.27%
1,475,000
SC 13G

Recent SEC filings of Corbus Pharmaceuticals Holdings Inc

View All Filings
Date Filed Form Type Document
Jun 14, 2024
144
Notice of Insider Sale Intent
Jun 14, 2024
144
Notice of Insider Sale Intent
Jun 14, 2024
4
Insider Trading
Jun 03, 2024
4
Insider Trading
Jun 03, 2024
8-K
Current Report
Jun 03, 2024
4
Insider Trading
Jun 03, 2024
4
Insider Trading
Jun 03, 2024
4
Insider Trading
Jun 03, 2024
4
Insider Trading
Jun 03, 2024
4
Insider Trading

Peers (Alternatives to Corbus Pharmaceuticals Holdings Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
53.7B
6.8B
8.51% 7.74%
-8.99
7.84
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.3B
2.0B
8.81% -20.73%
-61.09
10.13
75.20% 68.82%
15.9B
2.5B
3.83% -12.90%
77.15
6.41
13.74% 186.89%
13.9B
3.8B
8.85% -0.77%
18.71
3.7
8.58% 129.81%
MID-CAP
5.2B
107.9M
-7.07% 79.45%
-9.53
48.09
54.84% -28.31%
5.1B
524.1M
0.17% -53.14%
-12.21
9.72
394.93% 39.61%
3.5B
251.0M
-2.92% -12.90%
-11.81
13.95
73.58% -86.73%
3.2B
240.7M
3.27% -27.64%
-6.79
12.77
-1.03% -213.92%
2.5B
813.8M
-1.46% -38.91%
-1.4K
3.03
56.43% 98.83%
2.0B
996.6M
11.55% 78.54%
-5.07
2.03
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-9.60% 21.75%
27.32
4.32
60.38% -34.49%
534.3M
881.7K
13.28% 545.16%
-15.83
481.06
-77.61% 33.36%
235.5M
4.2M
-30.45% 48.53%
-1.89
56.62
-66.30% 48.24%
22.1M
2.1M
36.17% 264.31%
-0.95
7.61
-13.45% 69.54%

Corbus Pharmaceuticals Holdings Inc News

Latest updates
MarketWatch16 hours ago

Corbus Pharmaceuticals Holdings Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2021Q42021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q22018Q12017Q42017Q32017Q22017Q1
Revenue---97.001376486581,2312861,7622,5742,59029,0951,8861,9271,091854950-7963501,294
Operating Expenses-9,998-13,97316,83816,06221,47135,20538,42531,64729,76427,68627,38928,40819,51815,98913,247-----
  S&GA Expenses-226-5,2775,5725,3415,3607,6827,7397,6996,2765,5345,2086,6253,7373,1812,988-----
  R&D Expenses-380-8,69611,26510,72116,11027,52330,68623,94823,48822,15222,18121,78415,78112,80810,260-----
Interest Expenses-Infinity%-390--391-401-646-684-45413.001021512934.002.002.005.00937*-----
Net Income-Infinity%-10,260--2,176-17,138-16,065-8,611-34,895-38,105-29,656-26,580-20,7902,153-26,234-17,306-14,601-12,069-----
Net Income Margin-42.5%-51.76*-36.33*-28.57*-28.70*-----------------
Free Cashflow-1173.3%-9,756909909-17,476-----------------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets344.8%12628.0036.0044.0052.0066.0074.0082.0096.0010812012114010296.0098.0065.0049.0068.0084.00101
  Current Assets416.8%12224.0031.0038.0046.0060.0067.0075.0088.0010011211213092.0085.0088.0055.0038.0058.0075.0093.00
    Cash Equivalents2.8%14.0014.0011.008.007.0017.0012.0026.0057.0025.0037.0036.0067.0085.0082.0063.0047.0032.0055.0073.0090.00
  Net PPE-15.6%1.001.001.001.001.002.002.002.002.002.003.004.004.004.004.005.005.005.005.003.003.00
Liabilities-18.2%29.0035.0036.0034.0035.0033.0032.0033.0035.0039.0042.0044.0049.0057.0067.0050.0043.0043.0038.0037.0059.00
  Current Liabilities-18.7%26.0032.0032.0016.0014.0013.0017.0016.0015.0017.0017.0019.0024.0032.0041.0042.0035.0035.0031.0029.0052.00
  Long Term Debt----11.0014.0016.009.0012.0014.0016.0019.0018.0018.0018.0018.00------
    LT Debt, Non Current----11.0014.0016.009.0012.0014.0016.0019.0018.0018.0018.0018.00------
Shareholder's Equity1504.3%97.00-6.900.0010.0016.0033.0042.0049.0061.0069.0078.0077.0092.0045.0029.0048.0023.006.0030.0047.0042.00
  Retained Earnings-1.6%-443-436-428-418-409-392-381-372-359-349-339-337-320-304-295-260-222-192-166-145-147
  Additional Paid-In Capital25.8%541430429428426425423422420419417414412349325309245199196193190
Shares Outstanding137.5%11.004.004.004.004.004.004.004.004.004.004.004.00---------
Float----35.00---31.00-202-----665---390-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-32.6%-7,967-6,008-7,176-7,800-15,114-7,454-7,245-12,229-10,615-9,702857-17,528-21,809-18,224-27,253-26,607-27,601-22,561-17,086-16,39010,318
  Share Based Compensation22.9%9827998218231,0261,2691,3461,5131,5921,7932,5992,5072,5802,3413,6313,3483,1383,0982,9782,8173,089
Cashflow From Investing-1045.6%-98,23510,38810,8968,8075,55011,780-5,971-18,69642,962-3,177284-13,098-57,42452.00-56.80-16.17-463-1,291-1,194-183-73.61
Cashflow From Financing5695.8%106,583-1,904-82018.00-113234-110-330-327768-102-25560,41421,73546,73243,47442,934753-24.65-19137,927
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

CRBP Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:  
Research and development$ 5,761,494$ 13,388,343
General and administrative3,861,2513,908,682
Total operating expenses9,622,74517,297,025
Operating loss(9,622,745)(17,297,025)
Other income (expense), net:  
Other income (expense), net2,909,097229,507
Interest expense, net(177,015)(678,022)
Change in fair value of derivative liability28,5680
Foreign currency exchange gain (loss), net(36,676)728
Other income (expense), net2,723,974(447,787)
Net loss$ (6,898,771)$ (17,744,812)
Earnings Per Share, Basic$ (0.83)$ (4.24)
Earnings Per Share, Diluted$ (0.83)$ (4.24)
Weighted Average Number of Shares Outstanding, Basic8,310,5084,181,556
Weighted Average Number of Shares Outstanding, Diluted8,310,5084,181,556
Comprehensive loss:  
Net Income (Loss)$ (6,898,771)$ (17,744,812)
Other comprehensive (loss) income :  
Change in unrealized (loss) gain on marketable debt securities(326,949)57,623
Total other comprehensive (loss) income(326,949)57,623
Total comprehensive loss$ (7,225,720)$ (17,687,189)

CRBP Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 14,103,120$ 13,723,681
Investments106,000,0917,182,325
Restricted cash284,950192,475
Prepaid expenses and other current assets1,308,3362,447,549
Total current assets121,696,49723,546,030
Restricted cash384,950477,425
Property and equipment, net821,526973,214
Operating lease right of use assets2,841,1893,062,920
Other assets0212,804
Total assets125,744,16228,272,393
Current liabilities:  
Notes payable189,818300,664
Accounts payable2,081,8123,178,516
Accrued expenses9,398,22511,030,506
Derivative liability10,88239,450
Operating lease liabilities, current1,477,6691,436,723
Current portion of long-term debt12,764,91515,908,214
Total current liabilities25,923,32131,894,073
Other long-term liabilities044,411
Operating lease liabilities, noncurrent2,855,1403,238,631
Total liabilities28,778,46135,177,115
Stockholders' equity  
Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding at March 31, 2024 and December 31, 2023.00
Common stock, $0.0001 par value; 300,000,000 shares authorized,10,507,237 and 4,423,683 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively1,050442
Additional paid-in capital540,875,910429,780,375
Accumulated deficit(443,582,754)(436,683,983)
Accumulated other comprehensive loss(328,505)(1,556)
Total stockholders’ equity96,965,701(6,904,722)
Total liabilities and stockholders’ equity$ 125,744,162$ 28,272,393
CRBP
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, an endocannabinoid small molecule drug for the treatment of obesity and related metabolic diseases; and lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial or the treatment of inflammation and fibrosis. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
 CEO
 WEBSITEcorbuspharma.com
 INDUSTRYBiotechnology
 EMPLOYEES33

Corbus Pharmaceuticals Holdings Inc Frequently Asked Questions


What is the ticker symbol for Corbus Pharmaceuticals Holdings Inc? What does CRBP stand for in stocks?

CRBP is the stock ticker symbol of Corbus Pharmaceuticals Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Corbus Pharmaceuticals Holdings Inc (CRBP)?

As of Fri Jun 14 2024, market cap of Corbus Pharmaceuticals Holdings Inc is 534.33 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CRBP stock?

You can check CRBP's fair value in chart for subscribers.

What is the fair value of CRBP stock?

You can check CRBP's fair value in chart for subscribers. The fair value of Corbus Pharmaceuticals Holdings Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Corbus Pharmaceuticals Holdings Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CRBP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Corbus Pharmaceuticals Holdings Inc a good stock to buy?

The fair value guage provides a quick view whether CRBP is over valued or under valued. Whether Corbus Pharmaceuticals Holdings Inc is cheap or expensive depends on the assumptions which impact Corbus Pharmaceuticals Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CRBP.

What is Corbus Pharmaceuticals Holdings Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 14 2024, CRBP's PE ratio (Price to Earnings) is -15.83 and Price to Sales (PS) ratio is 481.06. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CRBP PE ratio will change depending on the future growth rate expectations of investors.